Long-Acting Bronchodilators and Risk of Adverse Cardiovascular Events in Chronic Obstructive Pulmonary Disease: A Focused Critical Review

 

Long-Acting Bronchodilators and Risk of Adverse Cardiovascular Events in Chronic Obstructive Pulmonary Disease: A Focused Critical Review

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality worldwide. Long-acting bronchodilators (LABs) are the mainstay of pharmacological maintenance therapy for COPD. However, the possibility that use of LABs may lead to risk of cardiovascular events remains debated. The objective is to provide a critical review of methodologies employed to evaluate risk of cardiovascular events in patients with COPD using LABs.